


FORM PTO-1390 (REV. 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 2870/319	
INTERNATIONAL APPLICATION NO. PCT/US00/17098		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/622510	
INTERNATIONAL FILING DATE 21 June 2000 (21.06.00)		PRIORITY DATES CLAIMED 25 June 1999 (25.06.99)	
TITLE OF INVENTION GEL-BASED COSMETIC COMPOSITION			
APPLICANT(S) FOR DO/EO/US PAINTER, Rachel J.; COHEN, Isaac D.;			
Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information			
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.			
2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.			
3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) immediately rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).			
4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.			
5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))			
a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).			
b. <input type="checkbox"/> has been transmitted by the International Bureau.			
c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)			
6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2))			
7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))			
a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).			
b. <input type="checkbox"/> have been transmitted by the International Bureau.			
c. <input checked="" type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.			
d. <input type="checkbox"/> have not been made and will not be made.			
8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).			
9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).			
10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11. to 16. below concern other document(s) or information included:			
11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.			
12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.			
13. <input type="checkbox"/> A FIRST preliminary amendment.			
<input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment			
14. <input type="checkbox"/> A substitute specification.			
15. <input type="checkbox"/> A change of power of attorney and/or address letter.			
16. <input type="checkbox"/> Other items or information:			

EXPRESS NO. : EL594604390US
306274

U.S. APPLICATION NO. if known, see 37 C.F.R. 1.5 09/622510		INTERNATIONAL APPLICATION NO PCT/US00/17098		ATTORNEY'S DOCKET NUMBER 2870/319					
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$840.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) ... \$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$760.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 50%;">CALCULATIONS</th> <th style="width: 50%;">PTO USE ONLY</th> </tr> <tr> <td colspan="2" style="height: 100px;"></td> </tr> </table>		CALCULATIONS	PTO USE ONLY		
CALCULATIONS	PTO USE ONLY								
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 970.00					
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$					
Claims	Number Filed	Number Extra	Rate						
Total Claims	26 - 20 =	6	X \$18.00	\$108.00					
Independent Claims	3 - 3 =	0	X \$78.00	\$0.00					
Multiple dependent claim(s) (if applicable)			+ \$260.00	\$					
TOTAL OF ABOVE CALCULATIONS =				\$1078.00					
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$					
SUBTOTAL =				\$					
Processing fee of \$130.00 for furnishing the English translation later the <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	\$				
TOTAL NATIONAL FEE =				\$1078.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				+	\$				
TOTAL FEES ENCLOSED =				\$1078.00					
				Amount to be: refunded	\$				
				charged	\$				
a. <input type="checkbox"/> A check in the amount of \$_____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>05-1320</u> in the amount of \$1078.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>05-1320</u> . A duplicate copy of this sheet is enclosed.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESPONDENCE TO:									
Kenyon & Kenyon One Broadway New York, New York 10004			 SIGNATURE						
			Estelle J. Tsevdos Reg. No. 31,145 NAME						
			<u>August 17, 2000</u> DATE						

GEL-BASED COSMETIC COMPOSITIONField of the Invention

5 The invention relates to the field of cosmetics. More specifically, the invention relates to gel-based color cosmetics.

Background of the Invention

10 A majority of color cosmetics are formulated with one or more inorganic pigment particles which confer the desired color to the composition. These particles are normally iron oxides, or titanium dioxide, having particle sizes ranging from about .5-200nm. Obviously, these pigments are an essential part of color cosmetics, and yet the very nature of these particles makes it difficult to formulate a product around them. These particles are soluble in neither oil nor water, and therefore must simply be suspended in the oil or water vehicle making up the base of the product. To achieve this, particularly in a single phase product, it is usually necessary to incorporate one or more thickeners or suspending agents into the formula. Without these suspending agents, which are usually waxes, it is virtually impossible to make a stable single phase formulation, as all the pigment particles soon settle out. Unfortunately, the suspending agents, in performing their required function, make the formula thicker and heavier than might otherwise be desirable. The texture of such formulas may be unacceptable to some consumers, particularly in warmer weather, when the lightest possible makeup is desired. Also, the suspending agents can interfere with the purity of color achieved in the formula. Thus, to date it has proven difficult, if not impossible, to provide a stable color cosmetic that is substantially nothing more than a pure color suspension, without the addition of suspending agents. The present invention now provides a unique solution to this formulation problem.

Summary of the Invention

The invention relates to a cosmetic or pharmaceutical composition comprising an elastic, non-rigid, porous support in which a low-viscosity, gellant-containing, otherwise unstable cosmetic or pharmaceutical formulation is integrated. The support acts as a stabilizer for the formulation, thereby permitting the preparation of low-viscosity formulas, reducing or completely eliminating the need for thickeners or suspending agents to keep any included inorganic pigments from settling out. The invention also relates to a method of making a stable cosmetic composition comprising preparing a low-viscosity, gellant-containing, otherwise unstable cosmetic formulation, and incorporating the formulation into a porous, non-rigid support. Preferably, the method includes the steps of preparing the formulation under conditions which do not permit gelling, adding the ungelled formulation to a non-rigid porous support, and allowing the formulation to gel within the support. The formulation in the support is nearly water-thin and very lightweight, and is accessed by pressing on the surface of the support, with either the fingers or another applicator.

Detailed Description of the Invention

The use of sponges or other porous devices to apply cosmetics to the skin is of course well-known (e.g., EP 823228; US 5401113; CN 1073111; FR 2628394; US 4927283; DE 3615358; US 4706693) Unlike many other porous-type applicators, the present combination does not have a separate reservoir of the formulation to be applied, from which the formulation is ultimately drawn to supply the porous applicator; instead, the entire formulation is distributed integrally throughout the support, the combination of support and formulation itself acting as the sole reservoir and source of product to be applied. The present invention also differs from such cosmetic uses of sponges in that the sponge in

the present case is used essentially as a stabilizer for a very low viscosity cosmetic composition, which composition would be otherwise be unstable. By "otherwise unstable", as used in the present specification and claims, is meant a formulation that, because of its low viscosity, is unable to stably maintain a suspension of inorganic pigment; in other words, contained pigment particles would quickly settle out of the formulation upon resting.

Although the formulation is gel-based, it contains relatively low levels of gellant, so that the gelled formulation, in the absence of the support, is inadequate to support the heavy pigments. Too much gellant in the formulation will result in a hardening of the porous support, and no payoff of the formulation when the support is compressed. In other words, the gellant should be used at a level which would be inadequate to stably support the presence of pigment particles in the formulation. Although levels are low, the presence of the gellant is essential, however, to permit the formulation to set up within the sponge; otherwise, the formulation will simply drip out of the support. The amount of gellant to be used, in functional terms, is that amount that will produce a fluid consistency below that of a paste; preferably, the formulation is nearly water-thin. The amount used will of course vary in absolute terms depending upon the identity of the gellant used, but is readily determinable for any gellant of interest.

The identity of the gellant will depend on the identity of the phase to be gelled. If the gelled phase is an oil phase, the gellant can be selected from any oil-soluble gellants, such as dextrin fatty acid esters, such as dextrin palmitate; cholesterol and derivatives, such as lanosterol, silicone gellants, such as organopolysiloxane elastomers; oil soluble cellulose derivatives, such as ethyl cellulose, and polymers or mixed copolymers, such as ethylene/methacrylic acid copolymer, ethylene/acrylic acid

copolymer, or polyethylene. The oil base may be any cosmetically acceptable oil, either volatile or non-volatile, or a mixture of both. For example, suitable volatile oils include, but are not limited to, both cyclic and linear silicones, such as cyclomethicone; or straight or branched chain hydrocarbons having from 8-20 carbon atoms, such as decane, dodecane, tridecane, tetradecane, and C8-20 isoparaffins.

Non-volatile oils include, but are not limited to, vegetable oils, such as coconut oil, jojoba oil, corn oil, sunflower oil, palm oil, soybean oil; carboxylic acid esters such as isostearyl neopentanoate, cetyl octanoate, cetyl ricinoleate, octyl palmitate, dioctyl malate, coco-dicaprylate/caprate, decyl isostearate, myristyl myristate; animal oils such as lanolin and lanolin derivatives, tallow, mink oil or cholesterol; glyceryl esters, such as glyceryl stearate, glyceryl dioleate, glyceryl distearate, glyceryl linoleate, glyceryl myristate; non-volatile silicones, such as dimethicone, dimethiconol, dimethicone copolyol, phenyl trimethicone, methicone, simethicone; and non-volatile hydrocarbons, such as isoparaffins, squalane, or petrolatum.

The gelled phase may also be aqueous. In the case in which the base is aqueous, the gellant will be a water-soluble gellant, such as carbomer, hydroxypropyl methylcellulose, hydroxyethylcellulose, hydroxy propyl guar, hydroxypropyl cellulose, potato starch modified, or acrylates/C10-C30 alkyl acrylates crosspolymer. Although the advantage of the invention is particularly great for use with a single phase composition, it is also possible to employ the porous support concept with a low viscosity emulsion, either oil-in-water or water-in-oil, utilizing the appropriated gellant to gel the emulsion's external phase.

The amount of base in the formulation, whether single phase oil or water, or a water-and-oil emulsion, will be in the range of from about 30 to about 99.6% by weight of the formulation. In one

preferred embodiment, the base is an anhydrous oil base, and more preferably, a silicone base, and the gellant is a cholesterol derivative, such as lanosterol. When using a cholesterol derivative, the amount of gellant employed ranges from about 0.1 to about 10%, preferably about 0.1 to about 2%, by weight of the formulation.

The formulation may also contain additional components. Particularly in the case of a color cosmetic product, the formulation will contain one or more pigments, which may be organic, inorganic, or a combination thereof. Examples of useful pigments include, but are not limited, inorganic pigments such as iron oxides (yellow, red, brown or black), ferric ammonium ferrocyanide (blue), manganese violet, ultramarine blue, chrome oxide (green), talc, lecithin modified talc, zeolite, kaolin, lecithin modified kaolin, titanium dioxide (white) and mixtures thereof. Other useful pigments are pearlants such as mica, bismuth oxychloride and treated micas, such as titanated micas and lecithin modified micas.

Useful organic pigments include natural colorants and synthetic monomeric and polymeric colorants. Exemplary are phthalocyanine blue and green pigment, diarylide yellow and orange pigments, and azo-type red and yellow pigments such as toluidine red, litho red, naphthol red and brown pigments. Also useful are lakes, which are pigments formed by the precipitation and absorption of organic dyes on an insoluble base, such as alumina, barium, or calcium hydrates. Particularly preferred lakes are primary FD&C or D&C lakes and blends thereof. Also included are polymer pigments, e.g., nylon powder, polyethylene, and polyesters. The polyesters can include linear, thermoplastic, crystalline or amorphous materials produced using one or more diols and one or more dicarboxylic acids copolymerized with colorants. Other pigments to be used in the invention will be apparent to one of ordinary skill in the art.

5 The formulation can also be a non-makeup product, i.e., a
skincare product without added pigment. In this regard, the
formulation may also contain one or more active ingredients, such
as sunscreens, self-tanning agents, chemical exfoliators, such as
AHAs or BHAs, antioxidants, anti-irritants, anti-inflammatories,
vitamins, skin-whiteners, and the like. Additional components,
such as skin conditioners, emollients, fillers, powders, pigment
wetting agents, and other such materials as are consistent with
the intended use of the final product. The formulation is
10 characterized further, however, in containing less than about 5%,
preferably less than about 1.0%, by weight of waxes or suspending
agents. This is in contrast to normal low-viscosity compositions,
which would usually require about 10% of suspending agents in
order to keep suspended particles from settling out.

15 The formulation after preparation is added, in a pourable
state, to the porous, non-rigid support. As the amount of gellant
used is low, even a fully gelled formulation may be pourable into
the support. However, it is preferred that the formulation be
maintained in a non-gelled state until it is in the sponge, so
20 that the gel actually sets up within the support. Frequently, as
will be the case with an anhydrous oil base, the formulation will
be a hot pour, in which the formulation is added while at elevated
temperature to the support and allowed to cool, and gel, after it
has penetrated the support.

25 The support can be virtually any porous material that is
cosmetically acceptable, and compatible with the cosmetic
formulation to be added to it. The support will ordinarily be a
foam or a sponge, such as a natural sponge, a foamed rubber such
as natural rubber, synthetic polyisoprene, nitrile, neoprene,
30 ethylene propylene diene type M, or polyurethane, or a foamed
polyethylene. Pore size should be in the range of from about 300-
100 pores per inch. Care should be taken to ensure that the pore
size is no smaller than the size of any particles, such as

pigments or powders, found in the formulation, so as to avoid clogging of the pores by the particles.

The preparation of the final product is straightforward: after preparation of the formulation, the liquid formulation is poured into the support, or alternately, the support is dipped or immersed in the formulation. In the case of a formulation that has not been gelled prior to addition to the support, the composition comprising support and formulation is left at room temperature for a time sufficient for the gellant to set up the formulation within the support. This time will vary depending upon the set point of any given gellant, but will ordinarily be no longer than about 15 minutes within the support. The composition is then ready to use. Although the level of gellant is selected so as to produce an inherently unstable formulation, the formulation is sufficiently gelled within the support to prevent its running out of the support in an uncompressed state; however, because the level is so low, when pressure is applied to the support, whether by pressing of the fingers or the skin surface to which it will be applied, or by pressing of another applicator onto the support, the gel readily breaks, releasing a lightweight, non-pasty, non-waxy, substantially water-thin product which is easily applied to the skin. This delivery system also exhibits a unique, silky, luxurious feel to the touch.

The formulation of the invention in a preferred embodiment will be a color cosmetic, such as a blush, foundation, eyeshadow, mascara (hair or lash), lip gloss, and the like. However, it can also be a skin care product, such as sunscreen, self-tanner, moisturizer, anti-acne product, anti-wrinkle composition, and the like, or it can be a pharmaceutical product intended for topical application to the skin, for example, an antibiotic, a wound-healing agent, an anti-inflammatory, and the like.

For practical use, the invention will normally be placed in a cosmetic-type package, for example, a compact or jar, for ease

of handling, and to prevent drying out. However, it may also be used as an applicator itself, e.g. alone or on a stick-type device. The invention therefore also provides a unit package comprising the cosmetic composition described herein. The invention will be further elucidated by reference to the following non-limiting example.

5

EXAMPLES

Example 1

5 A formulation of the invention is prepared as follows:

<u>Material</u>	<u>Weight %</u>
red iron oxide	1.00
10 yellow iron oxide	2.00
black iron oxide	0.20
titanium dioxide	17.20
polyglyceryl-3 diisostearate	0.50
phenyltrimethicone	64.20
15 polymethyl methacrylate	7.00
lauroyl lysine	3.50
dimethicone/cyclomethicone	4.00
lanosterol	0.40

20 The composition is prepared as follows:

1. Pigments are mixed under a propeller in polyglyceryl-3 diisostearate and 20% phenyl trimethicone.
2. The pigment mixture is then run through a roller mill three
- 25 times until the pigments are thoroughly wet out.
3. All the materials but the lanosterol are mixed together until homogeneous.
4. The mixture is heated to 100-105°C.
5. Lanosterol is slowly added under mixing.
- 30 6. Mixing is continued for about 10 minutes or until all lanosterol goes into solution.
7. If the formulation is to be used hot, a sponge (e.g., Qosmedix non-latex hydrophilic open cell sponge, 200 pores per inch) is

immersed into the hot mixture until it is fully saturated, ordinarily about 5 minutes. Excess material is wiped off and the sponge is inserted into a compact.

- 5 8. If the formulation is to be applied at room temperature, the sponge is immersed into the mixture as described in paragraph 7. above, while the mixture is being agitated in order to preserve homogeneity while absorption is occurring.

00/27090

What we claim is:

- 5 1. A cosmetic or pharmaceutical composition comprising a non-rigid, porous support in which a low-viscosity, gellant-containing, otherwise unstable cosmetic or pharmaceutical formulation is incorporated.
- 10 2. The composition of claim 1 which comprises an oil phase.
3. The composition of claim 1 in which the formulation is a water-and-oil emulsion.
- 15 4. The composition of claim 2 which is anhydrous.
5. The composition of claim 2 in which the base comprises a silicone oil.
- 20 6. The composition of claim 2 in which the gellant is selected from the group consisting of cholesterol and derivatives thereof, dextrin fatty acid esters, silicone gellants, oil-soluble cellulose derivatives, and oil-soluble polymers.
- 25 7. The composition of claim 6 in which the gellant is a cholesterol derivative.
8. The composition of claim 7 in which the gellant is lanosterol.
- 30 9. The composition of claim 1 in which the porous support has a pore size of from about 100 to about 300 pores per inch.
10. The composition of claim 1 in which the porous support is made

of a material selected from the group consisting of a natural sponge, a foamed rubber or a foamed polyethylene.

11. The composition of claim 1 which also contains at least one pigment.

12. The composition of claim 11 which comprises an inorganic pigment.

13. The composition of claim 1 which contains substantially no waxes or suspending agents.

14. A method for making a cosmetic or pharmaceutical composition comprising (a) preparing a low viscosity, gellant-containing, otherwise unstable formulation; and (b) incorporating the formulation into a porous, elastic, non-rigid support.

15. The method of claim 14 in which the formulation is prepared under conditions which do not permit gelling of the formulation.

16. The method of claim 15 in which the formulation is permitted to gel within the support.

17. A composition prepared according to the method of claim 14.

18. A composition prepared according to the method of claim 15.

19. A composition prepared according to the method of claim 16.

20. The composition of claim 17 in which the formulation comprises an oil.

21. The composition of claim 20 in which the gellant is selected from the group consisting of cholesterol derivatives, dextrin fatty acid esters, silicone gellants, and oil-soluble polymers.

5 22. The composition of claim 21 in which the oil comprises a silicone oil.

23. The composition of claim 21 in which the gellant is a cholesterol derivative.

10

24. The composition of claim 21 in which the gellant is lanosterol.

15

25. A cosmetic composition comprising an elastic, non-rigid porous support into which a low-viscosity, cholesterol or cholesterol derivative gellant-containing, otherwise unstable formulation has been integrated, the formulation also comprising at least one inorganic pigment, and an anhydrous base.

20

26. The composition of claim 23 in which the gellant is lanosterol.

Pat. 2,485,000, 1950

Docket No.
2870/319

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

GEL-BASED COSMETIC COMPOSITION

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on August 17, 2000 as United States Application No. or PCT International Application Number 09/622,510

and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

WO US 00/17098

PCT

6/21/2000

☐

(Number)

(Country)

(Day/Month/Year Filed)

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

EL 59460865245

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/344,090

6/25/99

PENDING

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

US 00/17098

6/21/00

PENDING

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Estelle J. Tsevdos -- Registration No. 31,145

Send Correspondence to: Estelle J. Tsevdos, Ph.D., J.D.
KENYON & KENYON
One Broadway
New York, New York 10004

Direct Telephone Calls to: *(name and telephone number)*
 Estelle J. Tsevdos -- (212) 425-7200

Full name of sole or first inventor <u>Rachel J. Painter</u>	
Sole or first inventor's signature <u>Rachel Painter</u>	Date <u>10/16/00</u>
Residence 876 President Street, Apt. #4, <u>Brooklyn</u> , New York 11215 <u>NY</u>	
Citizenship US	
Post Office Address 876 President Street, Apt. #4, Brooklyn, New York 11215	

Full name of second inventor, if any <u>Isaac David Cohen</u>	
Second inventor's signature <u>Isaac David Cohen</u>	Date <u>10/16/00</u>
Residence 1939 East 9th Street, <u>Brooklyn</u> , New York 11223 <u>NY</u>	
Citizenship US	
Post Office Address 1939 East 9th Street, Brooklyn, New York 11223	